RU2455999C2 - Preparation for treating and preventing iron-deficient conditions in animals - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science. The preparation contains a mixture of colloidal iron, a ligand, zinc, cobalt, selenium and water. The ligand is presented by Triton X-100 (polyethylene glycol mono (tetramethylbutanol) phenyl ester) in the following proportions, mg: colloidal iron (III) 35.0-45.0; Triton X-100 0.2÷0.6; zinc (II) 0.1÷0.3; cobalt (II) 0.05÷0.15; selenium (IV) 0.02÷0.04 and water up to 1000.0.

EFFECT: preparation exhibits high therapeutic and preventive efficacy, low toxicity, keeps dispersion and shows high storage stability.

5 cl, 12 tbl, 13 ex

Description

The invention relates to the field of veterinary medicine and relates to means for treating and preventing animal diseases caused by a lack of iron in their body, mainly alimentary anemia, secondary anemia, as well as to increase the safety and productivity of farm and carnivorous animals.

At present, in Russia and in the countries of the former Soviet Union, the most common diseases of young animals of various animal species are iron deficiency anemia or alimentary hypochromic microcytic anemia.

Alimentary anemia (physiological anemia, iron deficiency anemia) is a disease characterized by a disorder of the blood-forming organs in young animals. This disease is found everywhere, mainly in the autumn-winter and early spring periods, mainly in piglets aged 5 to 35 days and less often in young animals of other animal species. In diseased animals, a decrease in the formation of red blood cells, a low hemoglobin content, a decrease in resistance to other diseases are noted, which causes significant economic damage to pig farming. In most households, the mortality rate reaches 10-15% (1).

Anemia develops as a result of deficiency in the diet or in violation of the assimilation of a number of substances by the body that ensure the normal functioning of the blood formation organs. These essential substances include: iron, zinc, cobalt, selenium, and vitamin B ₁₂ . Secondary anemia can develop as a result of invasive and infectious diseases or with blood loss.

The main cause of nutritional anemia is iron deficiency. Iron is an indispensable metal necessary for the life of the body. The biological role of iron in the body is that this important element is part of hemoglobin, a number of iron-containing proteins and enzymes involved in tissue oxidation (catalase, peroxidase), as well as in the composition of cytochromes, where this element promotes the movement of electrons in the respiratory chain.

It is known that 60 ÷ 72% of all iron in the body is part of hemoglobin, in the molecule of which contains 0.34% of iron. There are 4 heme rings in the hemoglobin molecule, in each of which porphyrin is bonded to one Fe ⁺⁺ iron atom.

Iron deficiency leads to a decrease in its entry into the bone marrow, as a result of which hemoglobin synthesis is disrupted and, therefore, the hemoglobin content in red blood cells decreases. At the same time, the number of red blood cells decreases. With the development of iron deficiency anemia, some intracellular functions are violated due to a decrease in the content of iron-containing proteins and enzymes, as well as a violation of their activity.

As a rule, iron is present in feeds in various compounds at a fairly high level, but this iron is practically inaccessible to the body of newborn piglets due to a sharp decrease in their body hemoglobin levels in the first hours after birth.

Due to the deficiency of exogenous bioavailable iron in the body, the biosynthesis of hemoglobin molecules, the formation of red blood cells, and the synthesis of blood plasma proteins are disrupted. This leads to an imbalance of all redox processes, a decrease in piglet resistance to secondary diseases, and ultimately to culling and death of young animals. Therefore, it is proposed to consider anemia as a general pathological process, accompanied by a violation of the activity of many organs and systems of the animal organism.

For hematopoiesis, a special role is also played by a group of trace elements of hemostimulating action: zinc, cobalt and selenium. When introduced in negligible amounts, they have a stimulating and biocatalytic effect on blood formation processes (2).

For the treatment and prevention of nutritional anemia, iron-containing drugs are used both for intramuscular administration and for oral administration.

Almost all known iron preparations for oral administration are poorly tolerated, causing dyspepsia. At the same time, the severity of diarrhea is the stronger, the more will remain in the intestines of not absorbed iron. In this regard, it is impossible to conduct a course of treatment to the end and achieve the desired results.

Injection preparations are mainly mixtures of iron with ligands of various origins: polyhydric alcohols (sorbitol), dextran, dextrin, etc., which are administered to animals mainly with the addition of various sets of trace elements salts.

Famous drug "Ferroglukin" for the treatment and prevention of nutritional anemia containing a mixture of iron with low molecular weight dextran and water in an effective ratio (3).

The well-known drug “Ferbitol” for the treatment and prevention of iron deficiency conditions, containing a mixture of iron with sorbitol, citric acid, dextrin as a stabilizer and water in an effective ratio (4).

A known drug for the treatment and prevention of anemia containing a mixture of iron with hydrazine hydrate and water in an effective ratio (5).

A known drug for the treatment and prevention of anemia, containing a mixture of iron with starch and water in an effective ratio (6).

Known drug for the treatment and prevention of nutritional anemia containing a complex compound of iron with a polymer ligand and water. As the polymer ligand, we use compounds obtained by the interaction of hydroxycarboxylic acid, polyhydric alcohol and an epoxy compound, or products obtained by the interaction of sucrose, polyhydric alcohol and an epoxy compound in an effective ratio (7).

Known drug "Microaneminum" for the treatment and prevention of alimentary anemia, containing a mixture of iron with low molecular weight dextran, copper and cobalt in the following quantities, mg:

Iron 45.0 ÷ 78.0 Copper 0.05 ÷ 0.50 Cobalt 0.05 ÷ 0.50 Dextran 1000.0 (8).

Known drug "Biofer" for the prevention of nutritional anemia, containing a liquid extract of aloe and an aqueous solution of ferroglukin in an effective ratio (9).

The well-known drug “Ferox” for the prevention of nutritional anemia is a Hanks solution enriched in cationic iron in a concentration of 1.0 ± 0.15% (10).

A known drug for the prevention of nutritional anemia of piglets containing a mixture of iron with low molecular weight dextran, copper, cobalt and selenium in the following ratio, mg:

Iron 15.0 ÷ 18.7 Copper 149.0 ÷ 179.0 Cobalt 134.0 ÷ 167.0 Selenium 5.5 ÷ 6.8 Dextran up to 100.0 ml (11).

The known drug Suiferrovit for the treatment and prevention of nutritional anemia containing a mixture of inactivated normal serum of pigs, iron with low molecular weight dextran, cobalt, copper, calcium, vitamins B ₁ , B ₂ , B ₆ , PP and water in an effective ratio (12) .

The known drug “Ursoferran-100” for the treatment and prevention of nutritional anemia containing, as an active substance, a complex of iron (III) - heptonic acid dextran and phenol as a preservative in an effective ratio (13).

Known drug "Bioferrinitis" for the treatment and prevention of iron deficiency in animals, containing a mixture of colloidal iron (III) with gluconic acid as a ligand, a set of trace elements and water, while in 1000.0 mg of the drug’s solution there is: Fe (III) 50 mg , Cu (II) 0.16 mg, Zn (II) 0.1 mg, Co (II) 0.12 mg, Se (IV) 0.00015 mg, and NaCl 0.9 mg (14).

Known antianemic and growth-promoting drug for animals "Hemovit-plus" containing a complex of iron, manganese, copper, zinc, cobalt, selenium and iodine with disodium or dipotassium salt of ethylenediamine-N, N ¹ -disuccinic acid and water in the following ratio of components, wt. .%:

Disodium or dipotassium salt of ethylenediamine-N, N ¹ - succinic acid 15.0 ÷ 25.0 Iron (III) 0.6 ÷ 5.0 Manganese (II) 0.5 ÷ 2.0 Copper (II) 0.05 ÷ 0.25 Zinc (II) 0.1 ÷ 1.5 Cobalt (II) 0.005 ÷ 0.05 Selenium (IV) 0.01 ÷ 0.03 Iodine (I) 0.01 ÷ 0.05 Water up to 100.0

in this case, their inorganic salts, such as sulfates or chlorides, are used as a source of iron (III) and microelements, and sodium selenic acid or selenic acid as a source of selenium (IV), and potassium or sodium iodide as a source of iodine (I) (fifteen).

Known antianemic and growth-promoting drug for animals containing a complex of iron, manganese, copper, cobalt, zinc, selenium and iodine with disodium or dipotassium salt of ethylenediamine-N, N ¹ -disuccinic acid and water in the following ratio, wt.%:

Disodium or dipotassium salt of ethylenediamine -N, N ¹ - succinic acid 15.0 ÷ 25.0 Iron (III) 1,5 ÷ 5,5 Manganese (II) 0.25 ÷ 3.0 Copper (II) 0.12 ÷ 0.55 Cobalt (II) 0.05 ÷ 0.3 Zinc (II) 0.05 ÷ 1.5 Selenium (IV) 0.03 ÷ 0.06 Iodine (I) 0.01 ÷ 0.08 Water up to 100.0

while it contains sodium iodide and / or potassium iodide as a source of iodine (I) (16).

Known antianemic and growth-promoting drug containing a chelate complex of iron, manganese, zinc, copper, cobalt, selenium and iodine with trisodium or dipotassium salt of methionine succinic (α-amino-γ-methylthiobutyric-N-succinic) acid and water in the following ratio of components, wt .%:

Trisodium Salt methionine succinic acid 15.0 ÷ 40.0 Iron (III) 1,0 ÷ 5,5 Manganese (II) 0.25 ÷ 3.0 Copper (II) 0.1 ÷ 0.55 Zinc (II) 0.1 ÷ 0.55 Cobalt (II) 0.02 ÷ 0.3 Selenium (IV) 0.02 ÷ 0.06 Iodine (I) 0.01 ÷ 0.08 Water up to 100.0 (17).

Known antianemic and growth-promoting drug for animals containing a complex of iron, manganese, copper, cobalt, selenium, zinc and iodine with disodium or dipotassium salt of ethylenediamine-N, N ¹ -disuccinic acid and water in the following ratio, wt.%:

Disodium or dipotassium salt of ethylenediamine-N, N ¹ - succinic acid 15.0 ÷ 25.0 Iron (III) 1,5 ÷ 5,5 Manganese (II) 0.25 ÷ 3.0 Copper (II) 0.12 ÷ 0.55 Cobalt (II) from more than 0.05 to 0.3 Zinc (II) 0.05 ÷ 1.5 Selenium (IV) from more than 0.03 to 0.06 Iodine (I) 0.01 ÷ 0.08 Water up to 100.0

at the same time, it contains sodium iodide and / or potassium iodide as a source of iodine (I) (18).

Known antianemic and growth-promoting drug for animals containing a complex of iron, manganese, copper, zinc, cobalt, selenium and iodine with disodium or dipotassium salt of ethylenediamine-N, N ¹ -disuccinic acid, a set of vitamins and water in the following ratio of components, wt.%% :

Disodium or dipotassium salt of ethylenediamine-N, N ¹ - succinic acid 15.0-35.0 Iron (III) 0.6 ÷ 4.0 Manganese (II) 0.5 ÷ 2.5 Copper (II) 0.05 ÷ 0.25 Zinc (II) 0.3 ÷ 2.5 Cobalt (II) 0.005 ÷ 0.05 Selenium (IV) 0.01 ÷ 0.03 Iodine (I) 0.03 ÷ 0.08

Vitamins:

BUT 0.006 ÷ 1.2 D ₃ 0.00006 ÷ 0.0015 E 0.1 ÷ 3.5 B ₁ 0.005 ÷ 0.2 B ₂ 0.01 ÷ 0.25 B ₃ 0.02 ÷ 0.3 B ₄ 5.5 ÷ 20.0 B ₅ 0.04 ÷ 1.4 B ₆ 0.005 ÷ 0.12 Water up to 100.0, -

in this case, their inorganic salts, such as sulfates or chlorides, are used as a source of iron (III) and trace elements, and sodium selenic acid or selenic acid is used as a source of selenium (IV), and potassium or sodium iodide as a source of iodine (I) (19).

Known drug for the treatment of iron deficiency anemia containing ferbitol and gelatin in the following ratio of components, wt.%:

Ferbitol 80.0 ÷ 99.0 Gelatin 1.0 ÷ 20.0 (20).

A known composition for the prevention and treatment of anemia of farm animals and poultry, containing a mixture of complexonates of iron, copper, zinc, cobalt, sodium and calcium with ethylenediamine-N, N ¹ -duccinic acid in the following ratio of components, wt.%:

Copper complexonate with ethylenediamine-N, N ¹ - succinic acid 0.45 ÷ 0.60 Zinc complexonate with ethylenediamine-N, N ¹ - succinic acid 1.40 ÷ 1.45 Cobalt Complexonate with ethylenediamine-N, N ¹ - succinic acid 0,075 ÷ 0,08 Sodium complexonate with ethylenediamine-N, N ¹ - succinic acid 42.0 ÷ 44.0 Calcium complexonate with ethylenediamine-N, N ¹ - succinic acid 12.0-13.0 Iron complexonate with ethylenediamine-N, N ¹ - succinic acid up to 100.0 (21).

A known drug for the prevention and treatment of anemia, the correction of metabolic disorders in farm animals, containing a mixture of iron and starch as a ligand, copper sulfate, manganese sulfate, pancreatic casein hydrolyzate and water in the following ratio, wt.%:

Iron 3.0 ÷ 3.5 Starch 16.0 ÷ 18.0 Copper sulfate 0.005 ÷ 0.006 Manganese Sulfate 0.005 ÷ 0.006 Casein Hydrolyzate Pancreatic 1,2 ÷ 1,5 Water up to 100.0 (22).

Known antianemic and growth-promoting drug for animals, containing a chelate complex of iron, manganese, zinc, copper, cobalt, selenium and iodine with disodium or dipotassium salt of ethylenediamine-N, N ¹ -disuccinic acid and water in the following ratio of components, wt.%:

Disodium or dipotassium salt of ethylenediamine-N, N ¹ - succinic acid 25.1 ÷ 57.5 Iron (III) 0.5 ÷ 5.5 Manganese (II) 0.25 ÷ 4.9 Zinc (II) 0.05 ÷ 2.0 Copper (II) 0.10 ÷ 0.55 Cobalt (II) 0.05 ÷ 0.3 Iodine (I) 0.01 ÷ 0.08 Selenium (IV) 0.01 ÷ 0.06 Water up to 100.0 (23).

Known iron-containing agent for the prevention and treatment of anemia in animals, containing irondextran and sorbitol in the following ratio, wt.%:

Iron Dextran 78.0 ÷ 90.0 Sorbitol 10.0 ÷ 22.0 (24).

The disadvantages of the known drugs are their limited therapeutic and prophylactic efficacy and toxicity due to the presence in their composition of a significant amount of unbound iron, dimensional heterogeneity of particles of iron-containing complexes and a change in their dispersion (formation of agglomerates) and storage stability, which leads to incomplete absorption of iron as a result lack or violation of the production of biologically active substances - hemostimulants in the body of sick animals.

Also known is the drug "Triton X-100" (polyethylene glycol mono (tetramethylbutanol) phenyl ether), the chemical formula C14H220 (C2H40) with n = 9 ÷ 10, molecular weight ~ 625 g / mol, viscous liquid, density 1.07 g / cm ³ , used mainly in biochemical and virological laboratories as a detergent in the isolation and purification of various biological products (25 ÷ 48).

The disadvantages of the above drugs for the treatment and prevention of iron deficiency in animals are partially eliminated in the preparation for the treatment and prevention of iron deficiency in animals, containing a mixture of colloidal iron (III) with polyoxyethylene lauric alcohol as a ligand, trace elements of copper (II), zinc (II), cobalt (II), selenium (IV) and water in the following ratio of components, mg:

Colloidal Iron (III) 50.0 ÷ 60.0 Polyoxyethylene lauric alcohol 0.1 ÷ 0.3 Copper (II) 0.1 ÷ 0.3 Zinc (II) 0.1 ÷ 0.3 Cobalt (II) 0.1 ÷ 0.3 Selenium (IV) 0.001 ÷ 0.005 Water up to 1000.0,

in this case, the preparation may additionally contain glucose in an amount of 30.0 ÷ 50.0 mg and polyvinyl alcohol in an amount of 0.2 ÷ 0.6 mg (49).

The specified drug is taken by the applicant as a prototype.

The disadvantages of the prototype drug are its low toxicity and high cost.

The problem to which the present invention is directed, is to expand the arsenal of drugs for the treatment and prevention of iron deficiency conditions in animals with high therapeutic and prophylactic efficacy, low toxicity and cost.

This problem was solved by creating a drug for the treatment and prevention of iron deficiency conditions in animals, characterized by the following set of signs. The proposed drug (the copyright name "Compligem") contains a mixture of colloidal iron (III) with a ligand, a set of trace elements and water, and as a ligand it contains the drug Triton X-100 (polyethylene glycol mono (tetramethylbutanol) phenyl ether), and as trace elements zinc , cobalt and selenium in the following ratio of ingredients, mg:

Colloidal Iron (III) 35.0 ÷ 45.0 Triton X-100 0.2 ÷ 0.6 Zinc (II) 0.1 ÷ 0.3 Cobalt (II) 0.05 ÷ 0.15 Selenium (IV) 0.02 ÷ 0.04 Water up to 1000.0.

Inorganic salts, such as chlorides, are used as a source of iron (III) and microelements, and sodium selenous acid or selenic acid is used as a source of selenium.

If necessary, to improve the absorption of iron in the animal’s body, the proposed preparation may additionally contain glucose, preferably in an amount of 30.0 ÷ 50.0 mg.

If necessary, to create the body of the animal depot of the proposed drug, it may additionally contain polyvinyl alcohol, preferably in an amount of 0.2 ÷ 0.6 mg.

The present invention includes the following set of essential features, providing a technical result in all cases for which legal protection is requested.

1. The drug for the treatment and prevention of iron deficiency in animals.

2. Colloidal iron (III) in an amount of 35.0 ÷ 45.0 mg.

3. Triton X-100 as a ligand in an amount of 0.2 ÷ 0.6 mg.

4. Zinc (II) in an amount of 0.1 ÷ 0.3 mg.

5. Cobalt (II) in an amount of 0.05 ÷ 0.15 mg.

6. Selenium (IV) in an amount of 0.02 ÷ 0.04 mg.

7. Water in an amount up to 1000.0 mg.

The signs of the invention, characterizing the proposed drug and coinciding with the signs of the prototype, including the generic concept, reflecting the purpose, are:

1. The drug for the treatment and prevention of iron deficiency in animals.

2. Colloidal iron (III).

3. Ligand.

4. Zinc.

5. Cobalt.

6. Selenium.

7. Water.

Compared with the prototype drug, an essential distinguishing feature of the invention is that it contains Triton X-100 as a ligand.

The present invention contains such other distinctive features expressing specific forms of execution or special conditions for its use.

1. The preparation contains inorganic salts, such as chlorides, as a source of colloidal iron (III) and microelements, and sodium selenic acid or selenic acid as a source of selenium.

2. The preparation additionally contains glucose, preferably in an amount of 30.0 ÷ 50.0 mg.

3. The preparation additionally contains polyvinyl alcohol, preferably in an amount of 0.2 ÷ 0.6 mg.

The present invention expands the arsenal of drugs for the treatment and prevention of iron deficiency in animals, has high therapeutic and prophylactic efficacy by reducing toxicity, good tolerance, maintaining dispersion and stability of the iron-containing complex during storage, as well as lower manufacturing costs. The cost of manufacturing the drug "Compligem" is two times lower than the cost of manufacturing the drug prototype.

The achievement of the technical result from the use of the present invention is explained by the fact that the authors of the present invention discovered a new property of Triton X-100 in the claimed concentration range as part of the Kompligem preparation - to stabilize colloidal iron (III) giving it pharmacological properties and an aggregatively stable form of a suspension of an iron-containing complex with prolonged storage.

As a result of the interaction of colloidal iron (III) particles with Triton X-100, strong physico-chemical bonds arise between them, leading to the formation of a surface on the colloidal iron (III) particles with hydrophilic properties, which gives the particles of the complex pharmacological properties. The degree of hydrophilization of colloidal iron (III) particles was evaluated by the heat of interaction of the starting ingredients.

Treatment of colloidal iron (III) with Triton X-100 in the claimed concentration range makes it possible to obtain an iron-containing complex of uniform size and maintain it in a dispersed and stable state for a long time. The resulting compound withstands boiling, as well as repeated freezing to -20 ° C, followed by thawing.

In addition, the presence in the proposed preparation of glucose in the claimed concentration improves the absorption of iron in the animal.

The presence in the proposed preparation of polyvinyl alcohol in the claimed concentration allows you to create in the body of the animal depot of the drug after its introduction. Adsorbed on the particles of the iron-containing complex, polyvinyl alcohol molecules form solvate shells around the particles of the complex and turn the complex suspension into a kinematically stable form, which leads to the formation of a drug depot when it is introduced into the animal body. The drug is deposited in the liver and blood organs. The deposition of the drug provides a better distribution of the active substance in the animal’s body, prolonging its action, does not cause an adverse reaction of its tissues and reduces the treatment time for sick animals. The drug enhances redox reactions and blood formation processes, increases the synthesis of hemoglobin, myoglobin, increases the permeability of cell membranes, activates water-salt metabolism, as well as the action of trace elements (selenium, iron, cobalt and zinc) enzymes.

In addition, the Kompligem preparation does not contain copper ions, since copper and zinc in total presumably cause Alzheimer's disease (50.51).

The effectiveness of the proposed drug is illustrated by examples of its use, which does not limit the scope of the invention.

Example 1

Ferric chloride (FeCl ₃ * 6H ₂ O) in an amount of 15.5 ÷ 16.0 kg is dissolved in 30 l of distilled water. The resulting solution was filtered and transferred to the reactor. With continuous operation of the stirrer, a saturated stream of saturated ammonium carbonate solution [NH ₄ (CO ₃ ) ₂ ] is fed into the reactor at an average speed of 100 cm ³ / min in a volume of 22–25 dm ³ to establish the pH of the reaction mixture in the range of 6.8–7 , 2. In the process of introducing into the reactor a saturated solution of ammonium carbonate in the range of pH 3.3-3.8, a gel of colloidal iron is formed, which is broken by vigorous stirring and the addition of a saturated solution of ammonium carbonate.

The resulting colloidal iron solution is ultrafiltered while dialysis with tap water to release the colloidal iron solution from ammonium chloride (NH ₄ Cl ₂ ) and carbon dioxide (CO ₂ ) resulting from the reaction of ferric chloride with ammonium carbonate. The end of dialysis is determined by the absence of chlorine ions in the water leaving the ultrafiltration apparatus in reaction with silver nitrate (AgNO ₃ ). At the end of dialysis, the pH of the colloidal iron solution is adjusted within 9.0 ÷ 9.2 by adding 10% sodium hydroxide (NaOH) solution and with constant stirring, the reaction mixture is left for 8 ÷ 10 hours. After that, the reaction mixture is neutralized by adding citric acid to a pH of 6.5–6.8 and heated to 80–85 ° C without turning off the stirrer. At this time, the color of the reaction mixture changes from red-brown to dark red (black) opalescent with the formation of a black cone in the solution, which indicates the receipt of colloidal iron. To obtain an iron-containing complex, a mixture of Triton X-100, glucose and polyvinyl alcohol is added to a hot solution of colloidal iron so that the final concentration of Triton X-100, glucose and polyvinyl alcohol in 1000.0 mg of the drug is 0.2 ÷ 0, 6 mg; 30.0 ÷ 50.0 mg and 0.2 ÷ 0.6 mg, respectively. As a result of the interaction of colloidal iron particles with Triton X-100 in the claimed concentration, strong physico-chemical bonds arise between them, which preserve the dispersion and stability of the iron-containing complex during storage and the formation of a hydrophilic surface on the colloidal iron particles, which gives the particles of the obtained complex pharmacological properties.

Glucose in the claimed concentration range is used in the preparation to improve iron absorption in the animal.

Polyvinyl alcohol in the claimed concentration range is used to create the proposed preparation in the animal depot body after its administration.

The colloidal iron content in 1000.0 mg of the drug should be 35.0 ÷ 45.0 mg. If the concentration of colloidal iron is different from the above, the solution is concentrated or diluted in an ultrafiltration unit.

After that, the solution is cooled to 60 ° C, filtered through an ion exchange resin, the volume of the complex obtained is measured, and a set of trace elements in the form of their salts are added to it: ZnCl ₂ , CoCl ₂ * 6H ₂ O and Na ₂ SeO ₃ so that the content Zn ⁺⁺ and Co ⁺⁺ ions in 1000.0 mg of the preparation were 0.1–0.3 mg and 0.05–0.15 mg, respectively, and Se ⁺⁺ in the range 0.02–0.04 mg. In this case, each salt is dissolved separately in 0.5 l of distilled water, the solution is brought to a boil, and the boiling solution is introduced in a thin stream into the solution of the iron-containing complex with vigorous stirring. The drug is obtained in the form of an aqueous solution, which is a dark brown liquid with a pH of 6.5 ÷ 7.5.

The optimal formulation of the proposed drug are shown in table 1.

The resulting preparation is subjected to control for specific activity, as well as clinical, biological and therapeutic tests in laboratory and farm animals, as well as carnivores.

The control drug Kompligem is used to treat and prevent animal diseases caused by a lack of iron in their body, mainly nutritional anemia, secondary anemia, as well as to increase the safety and productivity of farm and carnivorous animals. The drug is administered to animals intramuscularly in the neck or thigh once a day.

For prophylactic purposes, the drug is administered to animals once in the following doses:

- for cows 20 ÷ 40 days before calving - 500 ÷ 1000 mg per 40 kg of live weight;

- calves 1 ÷ 2 days of age - 2000 ÷ 4000 mg;

- pregnant pigs for 20 ÷ 25 days before farrowing - 3000 ÷ 5000 mg;

- piglets 2 ÷ 4 days of age - 1000 ÷ 2000 mg depending on weight;

- dogs and fur animals - 500 mg per 10 kg of live weight;

- for cats and rabbits - 100 mg per 1 kg of live weight.

For therapeutic purposes - in the same doses twice with an interval of 10-14 days.

For a comparative verification of the effectiveness of the Kompligem preparation and the prototype preparation, 3 series of the indicated preparations were made, one for different concentrations of the ingredients of the preparations.

Example 2

Tests to determine the bioavailability of colloidal iron from the drug "Compligem", obtained as described in example 1, and containing, mg:

Colloidal Iron (III) 40,0 Triton X-100 0.4 Zinc (II) 0.2 Cobalt (II) 0.1 Selenium (IV) 0,03 Water up to 1000.0,

carried out in comparison with the prototype preparation on male mongrel white rats weighing 150 ÷ 200 g. For the experiment, three groups of animals of 10 animals each were formed. Animals with iron deficiency anemia were selected in the first and second groups, and normal rats as a control in the third group. The animals of the first and second groups were injected subcutaneously with the Kompligem drug and the prototype drug, respectively, in doses of 200 mg. After 2, 4 and 6 hours after drug administration, blood was taken from animals and the serum iron content was determined. It was found that in animals with iron deficiency, the iron content in the blood serum taken 4 hours after drug administration was the same.

Example 3

Tests of the drug "Compligem", manufactured as described in example 1, and containing, mg:

Colloidal Iron (III) 40,0 Triton X-100 0.4 Zinc (II) 0.2 Cobalt (II) 0.1 Selenium (IV) 0,03 Water up to 1000.0,

acute toxicity.

The test was carried out according to GFK1, issue 2, 1987, p.182 on healthy white mice of both sexes weighing 19 ÷ 21 g. Each series of the drug was tested on 5 mice, test doses were diluted 2 times with water for injection and administered to the mice intraperitoneally in an amount 200 mg Animals were monitored for 48 hours. At the end of the experiment, the mice underwent an autopsy, and no specific pathologies were detected. The death of animals was also not observed in any group. Studies have shown that the main parameters of acute toxicity - the minimum lethal dose and LD ₅₀ were not achieved in laboratory animals, despite the use of doses that are maximum possible for the chosen routes of administration - 200 mg.

Thus, the drug "Compligem" is non-toxic for this type of animal.

Example 4

Tests of the drug "Compligem", manufactured as described in example 1, and containing, mg:

Colloidal Iron (III) 40,0 Triton X-100 0.4 Zinc (II) 0.2 Cobalt (II) 0.1 Selenium (IV) 0,03 Water up to 1000.0,

for subchronic toxicity on the basis of the kennel of the Department of Internal Affairs of Vladimir in 24 dogs of the East European Shepherd breed weighing 40 ÷ 50 kg, which were under the same conditions of feeding and keeping. Experimental animals were divided into 3 groups of 8 animals each by analogy principle and blood was taken for hematological examination. The drug "Compligem" was administered intramuscularly three times with an interval of 10 days in the following doses:

Group 1 - 6000 mg (three times the therapeutic dose);

Group 2 - 2000 mg (therapeutic dose);

3 group - control group (2000 mg of physiological saline).

Throughout the experiment, the clinical condition of the dogs was monitored. A day after the last injection of the drug, blood was taken for studies (the number of red blood cells, white blood cells, hemoglobin, white blood cell count). In the course of the experiment, the death of animals and the skin-irritating (allergic) effect on the animal organism were not noted. The results of clinical and biological studies are presented in table 2.

According to the data in table 2, it was found that with a three-time administration of a 3 times increased therapeutic dose (6000 mg) of the drug (1 group of animals) and a therapeutic dose (2000 mg) of the drug (2 group of animals), all clinical and biological blood parameters in the experimental animals were in within the physiological norm and did not differ from similar indicators of the control group of animals.

Thus, the data obtained indicate that prolonged use of the drug "Compligem" does not have a toxic effect and does not cause functional changes in the body of dogs. An analysis of the results indicates the safety of the drug for animals.

Example 5

A study was conducted of the drug "Compligem", manufactured as described in example 1, and containing, mg:

Colloidal Iron (III) 40,0 Triton X-100 0.4 Zinc (II) 0.2 Cobalt (II) 0.1 Selenium (IV) 0,03 Water up to 1000.0,

on the cumulative effect on 120 heads of white rats weighing 120 ÷ 160 g, which was administered the drug for 3 months at a dose of 500 mg with an interval of 14 days. Control animals were injected with 0.5 cm ^{3 of} isotonic sodium chloride solution. After the experiment, the animals were decapitated, blood was collected and the kidneys and liver were removed. For each exposure, 10 rats were used. Certain weights of liver and kidney tissue, as well as blood serum, were taken, placed in bottles, dried at 105 ° C to constant weight, and ashing was performed in the presence of nitric acid. Crude ash was calcined at 500 ° C and, after cooling, it was dissolved in 0.1N HNO ₃ , filtered, and the content of elemental iron in the tissues was determined by atomic absorption spectroscopy. The results of studies to determine the content of elemental iron in blood serum, liver and kidneys are presented in table 3.

According to the data in Table 3, after administration of the Compligem drug to rats for 3 months, there was a significant increase in the iron content in the blood serum, kidneys and liver by comparison with the control. This indicates that the body absorbed colloidal iron from the drug and included its serum proteins and hemoglobin, as well as the deposition of iron in liver cells. The content of elemental iron in these organs and tissues of experimental animals was within the physiological norm. Thus, during the long-term administration of the Kompligem animal to animals, there was no cumulative accumulation of iron in either the liver, kidneys, or blood serum over the study period.

Example 6

A study was conducted of the drug "Compligem", manufactured as described in example 1, and containing, mg:

Colloidal Iron (III) 40,0 Triton X-100 0.4 Zinc (II) 0.2 Cobalt (II) 0.1 Selenium (IV) 0,03 Water up to 1000.0,

on the mutagenic effect on white male rats weighing 210–230 g. Groups of 6–10 animals each were formed from animals. The drug "Compligem" was administered to male white rats intramuscularly at 200 mg three times a month. The males were planted to the females on 7–10 days after drug administration with the aim of fertilization. Pregnant animals were opened on the 17th – 19th day of pregnancy, the number of yellow bodies of pregnancy, the number of living and dead embryos were counted. Each female was determined by general embryonic, preimplantation and postimplantation mortality. For anatelophase analysis, the bone marrow of the femurs of male rats was used, which was removed immediately after decapitation of the animal. Analysis of anatelophases was performed on bone marrow preparations stained with acetocarmine. Chromosome and chromatid bridges, single and paired fragments, and adhesions were taken into account. From each animal, at least 300 cells were analyzed. The percentage of chromosomal rearrangements and the mitotic index were calculated. The results of cytogenetic analysis of brain cells at the stages of metaphase and anaphase are presented in table 4.

According to the data in Table 4, the number of chromosomal aberrations in animals exposed to the Kompligem drug both in a single and repeated experiment did not significantly differ from the control and did not go beyond the boundaries of the spontaneous mutation level for this animal species.

Mutagenic effect of the drug "Compligem" after a month of exposure are presented in table 5.

The study of germ cells of animals exposed to Compligem at all stages of spermatogenesis showed the absence of increased fetal death before and after implantation.

Metaphase analysis of bone marrow cells in white rats after the use of the drug "Compligem" are presented in table 6.

Studies have shown that a single and multiple use of the drug "Compligem" does not cause mutagenic rearrangements in the animal body.

Example 7

A study was conducted of the drug "Compligem", manufactured as described in example 1, and containing, mg:

Colloidal Iron (III) 40,0 Triton X-100 0.4 Zinc (II) 0.2 Cobalt (II) 0.1 Selenium (IV) 0,03 Water up to 1000.0,

on the pharmacokinetic effect in 36 rats weighing 120 ÷ 200 g. The animals were divided into two groups. The first group of animals was administered the drug "Compligem" at a dose of 200 mg / head. The animals of the second group were injected with physiological saline in the same amount. After 0.5; 1.0; 2.0; 3.0; 5.0 and 24.0 h of animals were decapitated, blood was collected and the kidneys and liver were removed. Certain weights of liver and kidney tissue, as well as blood serum, were placed in boxes, dried at 105 ° C to constant weight, and ashing was performed in the presence of nitric acid. Crude ash was calcined at 500 ° С and, after cooling, it was dissolved in 0.1N НNO ₃ , filtered and the content of elemental iron in tissues was determined using atomic absorption spectroscopy. For each exposure, 2–3 rats were used. Data on the content of elemental iron in the blood and liver are presented in table 7.

The research results presented in table 7 show that after administration of the Compligem drug to rats, there was a slight increase in the iron content in the blood serum and liver after 30–60 minutes. This indicates that the body absorbed rat colloidal iron from the drug and included its whey proteins, as well as the deposition of iron in liver cells.

Example 8

Comparative tests of the effectiveness of the 1st series of the drug "Compligem", manufactured as described in example 1, and containing, mg:

Colloidal Iron (III) 35.0 Triton X-100 0.2 Zinc (II) 0.1 Cobalt (II) 0.05 Selenium (IV) 0.02 Water up to 1000.0,

and the 1st series of the prototype drug in the prevention of nutritional anemia of piglets and their effect on the growth energy and development of animals.

The volumetric doses and the timing of the intramuscular administration of both drugs to animals in this experiment were chosen the same.

For research, three groups of piglets of 5 goals in each of one litter were formed. The experiments were carried out in triplicate. The first group of 3-day-old piglets was injected with 1500 mg of the Compligem preparation into the behind-the-ear area of the body. The second group of animals was injected in the same manner with 1500 mg of the prototype drug. The third group served as control. Repeated injections of antianemic drugs were performed after 10 days.

A blood test was performed on 3, 10, 21, and 28 days of animal life. The most severe course of anemia was observed in the control group at 3 weeks of age. Table 8 presents the hematological parameters of piglets of this age. The growth rate was determined by the live weight of the piglets at weaning for 28 days.

According to table 8, the drug "Compligem" is not inferior to the prototype in its anti-anemic effect for piglets.

Thus, the drug "Compligem" has a fairly high efficiency in the prevention of nutritional anemia in piglets.

Example 9

Comparative tests of the effectiveness of the 1st series of the drug "Compligem", manufactured as described in example 1, and containing, mg:

Colloidal Iron (III) 35.0 Triton X-100 0.2 Zinc (II) 0.1 Cobalt (II) 0.05 Selenium (IV) 0.02 Water up to 1000.0,

and the 1st series of the prototype drug for the prevention of alimentary anemia in 60 suckling pigs in a pig complex of Vladimirsky CJSC of the Vladimir Region. 2 groups were formed from piglets. The first group of animals at the age of 4 days was injected intramuscularly with the drug “Komligem” at a dose of 2000 mg, and the second group of piglets of the same age was injected intramuscularly with the prototype drug at a dose of 2000 mg. After 14 days, the injections were repeated. The research results are presented in table 9.

The results of the studies, shown in table 9, indicate that two-time administration of anti-anemic drugs to piglets led to an increase in hemoglobin, red blood cells, hematocrit, and total protein in the blood serum of animals of both groups.

Intramuscular administration of antianemic agents also contributed to an increase in safety and average daily gain in live weight in piglets of both groups.

Example 10

Comparative tests of the effectiveness of the 2nd series of the drug "Compligem", manufactured as described in example 1, and containing, mg:

Colloidal Iron (III) 40,0 Triton X-100 0.4 Zinc (II) 0.2 Cobalt (II) 0.1 Selenium (IV) 0,03 Water up to 1000.0,

and the 2nd series of the prototype drug for antianemic activity in puppies in the clinic "Artemis" in Vladimir. For research, two groups of animals were formed with 5 animals in each 5-day age from one litter. The animals were administered the Kompligem drug and the prototype drug at a dose of 500 mg each intramuscularly on the 3rd day of life, and then 500 mg after 10 days.

The comparative effectiveness of the drugs was determined by hematological parameters.

The research results are presented in table 10.

According to the data of table 10, when using both iron-containing preparations, the hematological parameters of blood in puppies are improved. After a 30-day period, blood was collected from both groups of puppies to determine hemoglobin. As a result, an increase in the hemoglobin content in the blood of animals was found, which indicates the antianemic effect of the drugs.

Example 11

Tests of the therapeutic and prophylactic properties of the 2nd series of the Kompligem preparation, made as described in Example 1 and containing, mg:

Colloidal Iron (III) 40,0 Triton X-100 0.4 Zinc (II) 0.2 Cobalt (II) 0.1 Selenium (IV) 0,03 Water up to 1000.0,

in the conditions of the SEC “Kommunar” of the Suzdal district of the Vladimir region.

In the process of testing, 496 heads of pigs of various age and gender groups were involved (piglets at the age of 0-4 months, pregnant sows at the age of 2-4 years).

The study of the therapeutic and prophylactic effect of the use of the Kompligem preparation was carried out for various metabolic disorders in animals: edematous disease of piglets, growth retardation and development of young animals, impaired reproduction of animals. In addition, we studied the effect of drug treatment of pregnant sows (2-4 weeks before farrowing) on the viability of the offspring received from them.

The diagnosis of the disease was made on a commission basis: on the basis of clinical signs and laboratory data. The therapeutic efficacy of Kompligem was judged by the disappearance of the clinical symptoms of the disease, the lag of animals in growth and development, an increase in weight gain and laboratory data.

The prophylactic efficacy of the drug was taken into account by the percentage of diseased and non-diseased animals in the groups to which the Kompligem drug was administered or not.

The drug "Compligem" was used in accordance with the developed instructions.

The drug "Compligem" was administered intramuscularly in the neck or thigh.

For prophylactic purposes, the drug was administered once in the following doses: to pregnant pigs 20–25 days before farrowing at a dose of 3000–5000 mg, to pigs of 2–4 days of age at a dose of 1000–2000 mg, depending on the weight of the animals.

For therapeutic purposes, the drug was administered in the same doses twice with an interval of 10-14 days.

As a result of the studies, it was found that after 2 injections of the drug with an interval of 10-14 days, all clinical symptoms of vitamin deficiency in piglets disappeared, and the animals themselves gained weight faster and caught up with their peers in growth and development.

The research results are shown in table 11.

The data in table 11 indicate that the complex treatment of edema, white muscle disease, and vitamin deficiency of piglets with the Kompligem drug (1–2 injections) together with other agents leads to recovery of 89–97% of the animals, and its single use in 1–2 weeks before weaning piglets can reduce the incidence of edematous disease by 89 ÷ 97%.

With a single administration of the Kompligem preparation to pregnant sows, 2–3 weeks before farrowing, more viable young animals were obtained. Mortality among newborns was reduced by 2.5–3 times compared with untreated animals. In addition, experimental pigs had at birth an average weight of 100 ÷ 120 g more than animals in the control groups.

As a result of the introduction of “Compligem” to newborn pigs of 2–4 days of age at a dose of 1000–2000 mg for the prevention of vitamin deficiency, no signs of the disease appeared in any animal during 3 months of observation.

The simultaneous use of the Kompligem preparation with various kinds of treatment for piglets (vaccination, deworming, etc.) made it easier to transfer procedures, relieve them of stress and increase the body's immune status.

Based on the data obtained, it should be concluded that the use of the Kompligem drug in pig breeding can dramatically reduce the incidence of young animals with secondary anemia, as well as various diseases caused by metabolic disorders and weakening of the animal’s immune status: vitamin deficiency, edema, white muscle disease, stunting and development etc. In addition, fortification of pregnant sows 2–3 weeks before farrowing allows for more viable piglets.

Example 12

The tests of the effectiveness of the 3rd series of the drug "Kompligem", manufactured as described in example 1, and containing, mg:

Colloidal Iron (III) 45.0 Triton X-100 0.6 Zinc (II) 0.3 Cobalt (II) 0.15 Selenium (IV) 0.04 Water up to 1000.0,

in the conditions of the Dzerzhinsky agricultural complex in the Gavrilovo-Posadsky district of the Ivanovo region in the prevention of diseases with a lack of macro- and microelements, as well as increasing the viability of the body of young cattle (cattle).

In total, 16 calves at the age of 1–2 days were used in the experiment. Two groups of calves were formed from them, 8 animals each, one experimental and the other control. Animals were selected on the basis of analogues: age 1 ÷ 2 days, black-and-white breed, weight 35 ÷ 40 kg.

The calves of the experimental group were administered the drug "Kompligem" intramuscularly in the thigh area at a dose of 3000 mg once.

The calves of the control group were not given drugs for the prevention of diseases with a lack of macro- and micronutrients.

During the studies, clinical examination of the calves was carried out, basic physiological parameters (temperature, pulse, respiration) were noted. It was noted that the calves of the experimental group after administration of the Kompligem preparation were more mobile, actively reacted to external stimuli, the appetite was more pronounced than that of the calves of the control group. In calves of the control group, signs of inhibition or disturbance of physiological functions were not observed.

At the end of the experiment, all calves were again taken blood samples for analysis. The research results are presented in table 12.

According to table 12, the level of hemoglobin, erythrocytes, and also some biochemical parameters in calves of the control group is slightly lower than in calves of the experimental group, which negatively affects the vital functions of the body of newborn animals and leads to a decrease in growth, and in the future, shortage of production.

Thus, the use of the Kompligem preparation activates the physiological functions of the animal’s body, prevents the development of microelementoses in the body, and also enhances hematopoiesis, which helps to increase hemoglobin synthesis and the level of red blood cells.

Example 13

Comparative tests of the therapeutic and prophylactic properties of the 3rd series of the Kompligem preparation, made as described in Example 1, and containing, mg:

Colloidal Iron (III) 45.0 Triton X-100 0.6 Zinc (II) 0.3 Cobalt (II) 0.15 Selenium (IV) 0.04 Water up to 1000.0,

and the 3rd series of the prototype drug in the conditions of the subsidiary farm of the Federal State Institution of Health Care of the 081/9 institution of the Ministry of Justice of the Russian Federation.

For the experiment, 2 groups of suckling piglets of 2–3 days old were formed. All piglets were in the same conditions. Prior to the experiment, all animals were weighed. The weight of the piglets was in the range of 1.0 ÷ 1.2 kg.

Piglets of the 1st group (control) in the amount of 12 animals were injected intramuscularly with a dose of 2000 mg in order to prevent iron deficiency anemia at a dose of 2000 mg according to the instructions for use.

Piglets of the 2nd group (experimental) in the amount of 8 goals were injected with the drug "Compligem" intramuscularly once in a dose of 1000 mg.

After the administration of the Kompligem preparation, pigs of the 2nd group showed no pain, redness at the injection site, all the pigs actively moved around the machine, there were no signs of depression, the appetite was preserved.

After the introduction of the prototype drug, 2 piglets of the 1st group showed slight redness at the injection site, with pressure on this area pain was expressed. The remaining piglets had no similar signs.

Animals were monitored daily for 12 days. Piglets of both groups were mobile, appetite was preserved, physiological functions were not impaired.

At the end of the experiment, a control weighing of the piglets was carried out. For the piglets of the experimental group, the weight gain over the past period of time was 106 ÷ 118 g per head, while the weight gain of the piglets of the control group was 85 ÷ 100 g.

Thus, the Kompligem preparation was highly effective in preventing iron deficiency anemia in piglets and increasing the gain in young animals, which is of great importance for the safety and livelihood of young farm animals in production conditions.

Information sources

1. Jonauskas L.D. Prevention of nutritional anemia of sucking piglets with iron supplements added to feed. Abstract. dis ... cand. vet. Sciences., - M., 1980.

2. Karput I.M. Hematological atlas of farm animals. - Minsk, Urajay, 1986

3. The regulations for the production of ferroglukin (with an iron content of 75 mg / ml). - Minsk Plant of Medications, 1968, 20 p.

4. Auth. testimonial. USSR No. 306847, A61K 25/02, 06/21/1971

5. Auth. testimonial. USSR No. 355955, A61K 25/02, 10.23.1972

6. Auth. testimonial. USSR No. 683745, A61K 33/26, 09/05/1979

7. Auth. testimonial. USSR No. 730276, A61K 33/26, 39/00; 04/25/1980

8. Auth. testimonial. USSR No. 1328956, A61K 33/26, 1984

9. Manual on the use of "Biofer" in veterinary medicine. Approved by the GUV Ministry of Agriculture and the Republic of Belarus 02.17.1995

10. Application No. 92006855/15 for the grant of a patent of the Russian Federation for an invention, А61К 33/26, 02.27.1995,

11. Auth. testimonial. USSR No. 1797196, A61K 33/04, 02/10/1996

12. Index of drugs by their pharmacological action and use. Warsaw, Polfa Scientific Information Center, 1987. - P.139.

13. General and clinical veterinary formulation: Reference book / Ed. prof. V.N. Zhulenko. - M .: Kolos, 1998 .-- P.203.

14. Veterinary drugs in Russia: Reference book / I.F. Klenova, N.A. Yaremenko. - M .: Selkhozizdat, 2000. - S.296-297.

15. Pat. RF №2203657; A61K 31/295, 31/00; A61P 7/00; 05/10/2003

16. Pat. RF №2234317; A61K 31/295, A61P 7/06; 08/20/2004

17. Pat. RF №2252020; A61K 31/194, 33/24, 31/295; A61P 7/06; May 20, 2005

18. Pat. RF №2263504; A61K 31/295; A61P 7/06; November 10, 2005

19. Application No. 2005102760/15 for the grant of a patent of the Russian Federation for an invention, А61К 33/24, 31/194; A61P 7/06; 07/20/2006

20. Pat. RF №2280457; A61K 33/26, 35/32; A61P 7/06; 07/27/2006

21. Pat. RF №2282441; A61K 31/295, 31/30, 31/315; A61P 7/06; August 27, 2006

22. Pat. RF №2302873; A61K 35/37, 33/34, 33/32, 33/26, 31/718; A61P 1/00; July 20, 2007

23. Pat. RF №2309739; A61K 31/295, 31/00; A61P 7/00; November 10, 2007

24. Pat. RF №2338516; A61K 31/047, 31/721; A61P 7/06; November 20, 2008

25. BME, M., publishing house "Owls. Encyclopedia ", 1977, v. 7, 176-177.

26. Pat. RF №2062111, А61К 39/02, 06/20/1996

27. Pat. RF №2077589, С12Р 19/30, 04/20/1997

28. Pat. RF №2105977, G01N 33/48, 02.27.1998

29. Pat. RF №2122211; G01N 33/569, A61K 39/12, 39/187; November 20, 1998

30. Pat. RF №2159251; С07К 14/705, 14/72; G01N 30/00; 11/20/2000

31. Pat. RF №2175445; G01N 33/48, 33/573, 33/84; 10/27/2001

32. Pat. RF №2180120; G01N 33/84, 33/577, 33/552; 02/27/2002

33. Pat. RF No. 2193204; G01N 33/569, 33/536; November 20, 2002

34. Pat. RF №2193770; G01N 27/12, 30/00; November 27, 2002

35. Pat. RF No 2208785; G01N 33/14; C12G 1/00; 07/20/2003 g.

36. Pat. RF №2214591; G01N 30/00, 33/02; 10/20/2003 g.

37. Pat. RF №2216743; G01N 33/571; A61K 39/005; November 20, 2003

38. Pat. RF №2225614; G01N 33/53; March 10, 2004

39. Pat. RF №2232818; C12P 19/34; СНН 21/04; July 20, 2004

40. Pat. RF No 2237719; C12P 19/04; A61K 39/02, 39/39; G01N 33/53; 10/10/2004

41. Pat. RF No 2237893; G01N 30/00, 31/00; С07С 205/06; 10/10/2004

42. Pat. RF №2315299; G01N 33/18, 33/14, 27/447; January 20, 2008

43. Pat. RF №2325171; A61K 35/16, 38/17; May 27, 2008

44. Pat. RF No. 2346051; C12Q 1/00; G01N 27/00; 02/10/2009

45. Pat. RF No. 2367449; A61K 35/16, 38/17; September 20, 2009

46. Pat. RF №2371477, C12N 5/00, 10.27.2009

47. http://www.liquid-phase.ru.

48. http://hghltd.yandex.net.

49. Pat. RF №2257213; A61K 33/26; A61P 3/02, 7/06; July 27, 2005 (prototype).

50. NewScientist.com news service 12 August 03 http://www.newscientist.com/news/news.jsp?id=ns99994045 based on Proceedings of the National Academy of Sciences (DOI: 10.1073 / pnas. 1832769100).

51. New Scientist print edition, 3 August 2002.

Table 1 Optimal compositions of the Compligem preparation for the treatment and prevention of iron deficiency in animals Name of ingredients Recipe mg Minimum Average Maximum Colloidal iron 35.0 40,0 45.0 Triton X-100 0.2 0.4 0.6 Glucose 30,0 40,0 50,0 Polyvinyl alcohol 0.2 0.4 0.6 Zinc 0.1 0.2 0.3 Cobalt 0.05 0.1 0.15 Selenium 0.02 0,03 0.04 Water up to 1000.0 up to 1000.0 up to 1000.0

table 2 Hematological indications of blood of dogs when using the drug "Compligem" (n = 3) Indicators Group one 2 3 Dose of Compligem 6 cm ³ 2 cm ³ The control Hemoglobin (g%) 11.9-13.2 11.2-13.6 10.5-11.3 Red blood cells (million / mm) 7.4-8.8 7.6-8.9 7.0-8.7 White blood cells (thousand / mm) 9.1-10.2 9.0-10.5 8.9-10.0 White blood cell count Basophils one one 0 Eosinophils four 3 5 N. segmented 55 61 60 Lymphocytes 32 33 29th Monocytes 2 2 one Albumin (%) 40.2-42.3 40.0-41.8 41.2-42.9 Alpha globulins (%) 17.9-18.1 17.4-18.2 18.0-19.0 Beta Globulins (%) 20.3-22.1 21.0-23.0 21.0-22.9 Gamma globulins (%) 17.2-19.2 17.0-18.5 16.9-18.1 Urea (mmol / L) 4.4 4.0 4.0

Table 3 The accumulation of iron in the blood serum, liver and kidneys in rats after administration of the drug "Compligem" (n = 3) Groups of animals The iron content, mcg% The hemoglobin content, g% Liver Kidney Blood serum The control 263.0 ± 12.1 193.0 ± 10.1 169.0 ± 7.9 16.0 ± 0.3 Experience 353.0 ± 1.2 213.0 ± 21.2 235.0 ± 11.0 17.6 ± 0.3

Table 4 Cytogenetic analysis of bone marrow cells of animals exposed to the Compligem preparation under conditions of single and repeated injections (n = 3) One-time experience Metaphase Analysis Single fragments Paired fragments Total HA The control 450 2.6 ± 0.9 0.26 ± 0.1 2.9 ± 0.9 Experience 350 2.5 ± 0.9 P> 0.05 0.28 ± 0.2 2.8 ± 0.9 Monthly experience Metaphase Analysis Total HA Sticking together Lagging Mitotic index The control 1500 5.0 ± 0.10 0.2 ± 0.02 0.18 ± 0.06 1.88 ± 0.19 Experience 1500 5.06 ± 0.8 0.5 ± 0.27 P> 0.05 0.34 ± 0.15 1.86 ± 0.11

Table 5 The results of the determination of DLM in the sex cells of male rats exposed to the drug "Compligem" (n = 3) Group amount Death of fruits in% females VTB living the dead Before the implant. M ± m After the implant. M ± m Total M ± m The control thirty 13.41 11.65 1.00 6.97 ± 3.42 9.63 ± 1.23 17.75 ± 2.44 Compligem 33 13.78 12.23 0.67 7.85 ± 1.30 5.43 ± 0.85 13.96 ± 1.60

Table 6 Analysis of bone marrow cells in white rats under the influence of the drug "Compligem" (n = 3) Group Number of metaphases Number of single fragments Number of Paired Fragments Genes Total HA Experience 547 1.64 ± 0.43 P> 0.05 0.6 ± 0.34 P> 0.05 3.1 ± 0.6 P> 0.05 0.4 ± 0.31 The control 489 2.5 ± 0.37 0.7 ± 0.50 2.5 ± 0.3 0.4 ± 0.1

Table 7 The iron content in blood serum and liver in rats with the introduction of the drug "Compligem" (n = 3) Groups of animals Sampling time, hour The iron content, mcg% The hemoglobin content, g% liver blood serum The control 224 ± 0.12 153 ± 0.10 16.0 ± 0.3 Experience 0.5 hour
1.0 hour
2.0 hour
3.0 hour
5.0 hour
24.0 hour 250 ± 0.10
261 ± 0.11
271 ± 0.10
280 ± 0.10
289 ± 0.12
300 ± 0.11 170 ± 0.11
178 ± 0.12
188 ± 0.10
196 ± 0.09
190 ± 0.12
200 ± 0.11 16.1 ± 0.3
16.2 ± 0.4
16.4 ± 0.4
17.0 ± 0.5
17.2 ± 0.4
17.6 ± 0.3

Table 8 The effect of antianemic drugs on the hematological parameters of piglets and their live weight (n = 3) Groups Hemoglobin, g% The number of red blood cells, million / mm ³ Hematocrit,% Average live weight, kg Compligem 10.08 ± 0.46 6.98 ± 0.52 31.9 ± 0.37 6.88 10.05 ± 0.56 6.82 ± 0.60 32.0 ± 0.45 6.00 The control 7.2 ± 0.38 3.82 ± 0.42 26.0 ± 0.52 5.62

Table 9 Comparative efficacy of the Kompligem preparation and the prototype preparation according to hematological parameters, safety and average daily gain in live weight of piglets by 30 days of age (n = 3) Indicator A drug Compligem Prototype drug Hemoglobin, g% 11.08 ± 0.52 11.05 ± 0.49 Hematocrit 41.80 ± 1.10 40.80 ± 0.75 Red blood cells, mln / μl 7.30 ± 0.60 7.16 ± 0.51 Total protein, g% 6.05 ± 0.35 6.00 ± 0.23 Safety 0.95 0.90 Weight at weaning, kg 7.24 ± 0.34 6.98 ± 0.33

Table 10 Hematological blood counts in puppies (n = 3) Groups Age in days 5 twenty 40 Hemoglobin, g% Compligem 9.8 ± 0.21 11.7 ± 0.19 13.5 ± 0.23 Prototype drug 9.9 ± 0.17 12.6 ± 0.25 13.4 ± 0.16 Red blood cells, million / mm ³ Compligem 6.32 ± 0.22 7.50 ± 0.18 8.65 ± 0.22 Prototype drug 6.25 ± 0.19 7.46 ± 0.27 8.77 ± 0.15 Hematocrit% Compligem 40.4 ± 0.80 44.2 ± 0.90 45.6 ± 0.93 Prototype drug 39.6 ± 0.78 43.4 ± 0.85 43.8 ± 0.77

Table 11 Therapeutic and prophylactic effectiveness of the Kompligem drug in diseases of pigs Disease Age of animals Number of goals The course of treatment, days Efficiency% Note Violation of growth and development of the fetus (vitamin deficiency) 0 ÷ 3 months 98 10 ÷ 14 one hundred In conjunction with other events Edema 2.5 ÷ 3 months 41 10 ÷ 14 89.4 ÷ 97.3 White muscle disease 1 ÷ 2 months 112 10 ÷ 14 95.6 ÷ 97.2 Prevention of Secondary Anemia 2 ÷ 4 day 249 once one hundred -

Table 12 The results of checking the effectiveness of the use of the Kompligem drug for the prevention of macro- and microelement deficiency diseases, as well as increasing the viability of young cattle Groups The name of indicators Red blood cells, mln / μl White blood cells, thousand / μl Protein, g /% Ca, mg /% P, mg /% Carotene, mcg /% Experienced 7.0 ± 0.5 5.0 ± 0.4 7.5 ± 0.3 10.3 ± 0.2 5.5 ± 0.1 350 ± 10 Control 6.4 ± 0.4 5.2 ± 0.3 7.4 ± 0.4 10.5 ± 0.1 5.3 ± 0.2 325 ± 25

Claims (5)

1. The drug for the treatment and prevention of iron deficiency in animals, containing a mixture of colloidal iron with a ligand, zinc, cobalt, selenium and water, characterized in that it contains Triton X-100 (polyethylene glycol mono (tetramethylbutanol) phenyl ether) as a ligand the following ratio of components, mg:
Colloidal Iron (III) 35.0 ÷ 45.0 Triton X-100 0.2 ÷ 0.6 Zinc (II) 0.1 ÷ 0.3 Cobalt (II) 0.05 ÷ 0.15 Selenium (IV) 0.02 ÷ 0.04 Water up to 1000.0 2. The drug according to claim 1, characterized in that as a source of iron (III) and trace elements it contains their inorganic salts, such as chlorides. 3. The drug according to claim 1, characterized in that as a source of selenium it contains sodium selenate or selenic acid. 4. The drug according to claim 1, characterized in that it additionally contains glucose in an amount of 30.0 ÷ 50.0 mg. 5. The drug according to claim 1, characterized in that it additionally contains polyvinyl alcohol in an amount of 0.2 ÷ 0.6 mg.